In 2019, CREDENCE trial proved the efficacy of SGLT2 inhibitors for DKD: compared with that of the placebo group, the risk of renal composite endpoint events (ESRD, doubling of serum creatinine, and kidney-related death) was reduced by 34% in the caloglitazone group [44]. This evidence concerns the gene SLC5A2 and diabetic kidney disease.